BCL2L10 and melanoma: For the loss of function approach, we silenced BCL2L10 expression by shRNA in A375 (Figure 1D), one of the cell lines that expressed the highest levels of endogenous BCL2L10 among the melanoma cell lines tested (Figure 1A).